When can antiplatelet therapy be resumed or initiated in a patient recovering from recent dengue who now has a normal platelet count?

When to Resume or Start Antiplatelet Therapy After Recent Dengue with Normal Platelet Count

Resume antiplatelet therapy once platelet count has normalized (≥150 × 10⁹/L) and hemostasis is clinically stable, typically 24-72 hours after achieving normal counts, with the exact timing depending on bleeding risk and cardiovascular indication urgency.

Clinical Decision Framework

Immediate Assessment Required

Before resuming antiplatelet therapy, verify:

• Platelet count ≥150 × 10⁹/L (confirmed normal range)
• No active bleeding or bleeding signs in past 24-48 hours
• Stable hematocrit (no ongoing plasma leakage)
• Normal coagulation parameters if previously abnormal
• Cardiovascular indication urgency (recent stent, acute coronary syndrome, high-risk stroke)

Timing Algorithm Based on Cardiovascular Risk

HIGH-RISK CARDIOVASCULAR PATIENTS (resume earlier):

• Recent coronary stent (<3 months): Resume within 24-48 hours of platelet normalization 1, 2
• Recent ACS or stroke (<30 days): Resume within 24-48 hours of platelet normalization 3
• Dual antiplatelet therapy (DAPT) indication: Resume within 24-48 hours, prioritizing aspirin first if concerned 4

STANDARD CARDIOVASCULAR PATIENTS (resume cautiously):

• Stable coronary disease on single antiplatelet: Resume within 48-72 hours of platelet normalization 5
• Secondary stroke prevention: Resume within 48-72 hours of platelet normalization 3
• Peripheral artery disease: Resume within 48-72 hours of platelet normalization 5

Evidence-Based Considerations

Research specifically addressing dengue shows that continuation of single antiplatelet therapy during dengue with thrombocytopenia did not increase major bleeding risk compared to discontinuation 6. A large cardiovascular dengue cohort found 7-day major bleeding rates of only 0.61% in single antiplatelet users versus 0.34% in non-users 7. However, aspirin users demonstrated delayed platelet recovery (median 7.5 vs 4.0 days to recovery) 7.

For patients on DAPT during dengue, bleeding risk was higher (4.55% at 7 days) 7, supporting temporary interruption during acute thrombocytopenia but prompt resumption once normalized.

Specific Resumption Protocol

For Single Antiplatelet Therapy (Aspirin or Clopidogrel):

1. Confirm platelet count ≥150 × 10⁹/L on two consecutive measurements 12-24 hours apart
2. Verify no bleeding manifestations for 24 hours minimum
3. Resume at standard maintenance dose (aspirin 75-100 mg daily or clopidogrel 75 mg daily) 4
4. No loading dose needed unless acute coronary event occurred during dengue

For Dual Antiplatelet Therapy:

1. Prioritize aspirin resumption first within 24-48 hours of platelet normalization 1, 2
2. Add P2Y12 inhibitor 24 hours later if platelet count remains stable ≥150 × 10⁹/L
3. For recent stents (<6 weeks): Consider resuming both simultaneously if bleeding risk is low and stent thrombosis risk is high 1

Critical Pitfalls to Avoid

DO NOT resume antiplatelet therapy if:

• Platelet count <150 × 10⁹/L (even if rising)
• Active bleeding or bleeding within past 24 hours
• Hematocrit still fluctuating (suggests ongoing plasma leakage)
• Severe dengue manifestations still present (shock, organ impairment)

DO NOT delay resumption excessively:

• Withholding antiplatelet therapy beyond 72 hours after platelet normalization increases cardiovascular risk without additional safety benefit 1, 2
• For recent stents or ACS, each day without antiplatelet therapy increases thrombotic risk substantially 4

Special Populations

Patients requiring anticoagulation plus antiplatelet:

• Resume antiplatelet therapy only after platelet count ≥150 × 10⁹/L and ideally when count reaches ≥100 × 10⁹/L if on therapeutic anticoagulation 5
• Consider GI protection with proton pump inhibitor when resuming combination therapy 4

Elderly or high bleeding risk patients:

• Use the longer end of timing ranges (72 hours vs 24 hours)
• Consider single antiplatelet therapy even if previously on DAPT, then reassess need for DAPT after full recovery

Monitoring After Resumption

• Recheck platelet count 48-72 hours after resuming antiplatelet therapy
• Monitor for bleeding signs for first week
• Ensure platelet count remains ≥100 × 10⁹/L on follow-up; if drops below this, temporarily discontinue and reassess

The key principle is balancing cardiovascular thrombotic risk against residual bleeding risk, with normal platelet count being necessary but not always sufficient - clinical stability and absence of bleeding for 24-48 hours are equally important before resumption 7, 6, 8.